Checkpoint inhibition in myeloma

Autor Benson, Don M.
Vydáno v Hematology Am Soc Hematol Educ Program (2016)

Cancer Immunology at the Crossroads: Killer immunoglobulin-like receptors and tumor immunity

Autor Benson, Don M, Caligiuri, Michael A
Vydáno 2014

VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine

Autor Yang, Eric V., Donovan, Elise L., Benson, Don M., Glaser, Ronald
Vydáno 2007

TTP disease course is independent of myeloma treatment and response

Autor Hofmeister, Craig, Jin, Ming, Cataland, Spero R., Benson, Don M., Wu, Haifeng M.
Vydáno 2010

Curcumin Induces Pro-apoptotic Effects Against Human Melanoma Cells and Modulates The Cellular Response to Immunotherapeutic Cytokines

Autor Bill, Matthew A., Bakan, Courtney, Benson, Don M., Fuchs, James, Young, Gregory, Lesinski, Gregory B.
Vydáno 2009

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells

Autor Wang, Yufeng, Zhang, Yibo, Hughes, Tiffany, Zhang, Jianying, Caligiuri, Michael A., Benson, Don M., Yu, Jianhua
Vydáno v Clin Cancer Res (2018)

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

Autor Lin, Li, Benson, Don M., DeAngelis, Stephanie, Bakan, Courtney E., Li, Pui-Kai, Li, Chenglong, Lin, Jiayuh
Vydáno 2011

Serum free light chains in myeloma patients with an intact M-protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel ag...

Autor Mori, Sherry, Crawford, Brooke S, Roddy, Julianna VF, Phillips, Gary, Elder, Pat, Hofmeister, Craig C, Efebera, Yvonne, Benson, Don M
Vydáno 2011

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8(+) T cell function

Autor Petty, Amy J., Dai, Rui, Lapalombella, Rosa, Baiocchi, Robert A., Benson, Don M., Li, Zihai, Huang, Xiaopei, Yang, Yiping
Vydáno v JCI Insight (2021)

Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome

Autor Chu, Benjamin F., Shana’ah, Arwa, Hofmeister, Craig C., Benson, Don M., Sell, Megan, Tucker, Jill, Pichiorri, Flavia, Efebera, Yvonne A.
Vydáno v Eur J Case Rep Intern Med (2014)

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

Autor Sborov, Douglas W., Benson, Don M., Williams, Nita, Huang, Ying, Bowers, Mindy A., Humphries, Kristina, Efebera, Yvonne, Devine, Steven, Hofmeister, Craig C.
Vydáno v Br J Haematol (2015)

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

Autor Benson, Don M., Yu, Jianhua, Becknell, Brian, Wei, Min, Freud, Aharon G., Ferketich, Amy K., Trotta, Rossana, Perrotti, Danilo, Briesewitz, Roger, Caligiuri, Michael A.
Vydáno 2009

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Autor Martin, Thomas, Baz, Rachid, Benson, Don M., Lendvai, Nikoletta, Wolf, Jeffrey, Munster, Pamela, Lesokhin, Alexander M., Wack, Claudine, Charpentier, Eric, Campana, Frank, Vij, Ravi
Vydáno v Blood (2017)

Ninety-Minute Daratumumab Infusion is Safe in Multiple Myeloma

Autor Barr, Hallie, Dempsey, Jessica, Waller, Allyson, Huang, Ying, Williams, Nita, Sharma, Nidhi, Benson, Don M., Rosko, Ashley E., Efebera, Yvonne A., Hofmeister, Craig C.
Vydáno v Leukemia (2018)

Most Multiple Myeloma Patients have Low Testosterone

Autor John, Sonya, Sharma, Nidhi, Sborov, Douglas, Williams, Nita, Jones, Desirée, Benson, Don M, Efebera, Yvonne A, Rosko, Ashley E, Vincent, Jennifer, Hofmeister, Craig C
Vydáno v Leuk Lymphoma (2018)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Autor Cottini, Francesca, Huang, Ying, Williams, Nita, Bumma, Naresh, Khan, Abdullah M., Chaudhry, Maria, Devarakonda, Srinivas, Efebera, Yvonne A., Benson, Don M., Rosko, Ashley E.
Vydáno v Front Oncol (2021)

The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector

Autor Dong, Wenjuan, Wu, Xiaojin, Ma, Shoubao, Wang, Yufeng, Nalin, Ansel P., Zhu, Zheng, Zhang, Jianying, Benson, Don M., He, Kai, Caligiuri, Michael A., Yu, Jianhua
Vydáno v Cancer Discov (2019)

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma

Autor Benson, Don M, Panzner, Kathryn, Hamadani, Mehdi, Hofmeister, Craig C, Bakan, Courtney E, Smith, Megan K, Elder, Pat, Krugh, David, O’Donnell, Lynn, Devine, Steven M
Vydáno 2010

A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma

Autor Benson, Don M., Cohen, Adam D., Jagannath, Sundar, Munshi, Nikhil C., Spitzer, Gary, Hofmeister, Craig C., Efebera, Yvonne A., Andre, Pascale, Zerbib, Robert, Caligiuri, Michael A.
Vydáno v Clin Cancer Res (2015)

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Autor Benson, Don M., Hofmeister, Craig C., Padmanabhan, Swaminathan, Suvannasankha, Attaya, Jagannath, Sundar, Abonour, Rafat, Bakan, Courtney, Andre, Pascale, Efebera, Yvonne, Tiollier, Jérôme, Caligiuri, Michael A., Farag, Sherif S.
Vydáno 2012